CD146: a potential therapeutic target for systemic sclerosis

Lingling Zhang; Yongting Luo; Xiao Teng; Zhenzhen Wu; Mengtao Li; Dong Xu; Qian Wang; Fei Wang; Jing Feng; Xiaofeng Zeng; Xiyun Yan

doi:10.1007/s13238-018-0531-x

PDF(833 KB)

Protein Cell ›› 2018, Vol. 9 ›› Issue (12) : 1050-1054. DOI: 10.1007/s13238-018-0531-x

LETTER

CD146: a potential therapeutic target for systemic sclerosis

Author information +

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Lingling Zhang, Yongting Luo, Xiao Teng, Zhenzhen Wu, Mengtao Li, Dong Xu, Qian Wang, Fei Wang, Jing Feng, Xiaofeng Zeng, Xiyun Yan. CD146: a potential therapeutic target for systemic sclerosis. Protein Cell, 2018, 9(12): 1050‒1054 https://doi.org/10.1007/s13238-018-0531-x

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Akhmetshina A, Palumbo K, Dees C, Bergmann C, Venalis P (2012) Activation of canonical Wnt signalling is required for TGFbeta-mediated fibrosis. Nat Commun 3:735 CrossRef Google scholar

[2]	Bergmann C, Distler JH (2016) Canonical Wnt signaling in systemic sclerosis. Lab Invest 96:151–155 CrossRef Google scholar

[3]	Bhattacharyya S, Wei J, Varga J (2012) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42–54 CrossRef Google scholar

[4]	Dagur PK, McCoy JP, Jr (2015) Endothelial-binding, proinflammatory T cells identified by MCAM (CD146) expression: Characterization and role in human autoimmune diseases. Autoimmun Rev 14:415–22. CrossRef Google scholar

[5]	Distler O, Cozzio A (2016) Systemic sclerosis and localized scleroderma-current concepts and novel targets for therapy. Semin Immunopathol 38:87–95 CrossRef Google scholar

[6]	Duan H, Xing S, Luo Y, Feng L, Gramaglia I (2013) Targeting endothelial CD146 attenuates neuroinflammation by limiting lymphocyte extravasation to the CNS. Sci Rep 3:1687 CrossRef Google scholar

[7]	Ito T, Tamura N, Okuda S, Tada K, Matsushita M, Yamaji K (2017) Elevated serum levels of soluble CD146 in patients with systemic sclerosis. Clin Rheumatol 36:119–124 CrossRef Google scholar

[8]	Kaspi E, Heim X, Granel B, Guillet B, Stalin J (2017) Identification of CD146 as a novel molecular actor involved in systemic sclerosis. J Allergy Clin Immunol 5:1448–1451 CrossRef Google scholar

[9]	Katsumoto TR, Whitfield ML, Connolly MK (2011) The pathogenesis of systemic sclerosis. Annu Rev Pathol 6:509–537 CrossRef Google scholar

[10]	Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G (1987) Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47:841–845

[11]	Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY (2012) CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 13:6399–6406 CrossRef Google scholar

[12]	Luo Y, Duan H, Qian Y, Feng L, Wu Z (2017) Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis. Cell Res 27:352–372 CrossRef Google scholar

[13]	Tung HH, Lee SL (2017) Physical Binding of Endothelial MCAM and Neural Transmembrane Protease Matriptase-Novel Cell Adhesion in Neural Stem cell Vascular Niche. Sci Rep 7:4946 CrossRef Google scholar

[14]	Xing S, Luo Y, Liu Z, Bu P, Duan H, (2014) Targeting endothelial CD146 attenuates colitis and prevents colitis-associated carcinogenesis. Am J Pathol 184:1604–1616 CrossRef Google scholar

[15]	Zheng C, Qiu Y, Zeng Q, Zhang Y, Lu D (2009) Endothelial CD146 is required for in vitro tumor-induced angiogenesis: the role of a disulfide bond in signaling and dimerization. Int J Biochem Cell Biol 41:2163–2172 CrossRef Google scholar